A new cancer drug may be able to inhibit both tumor growth and the spread of aggressive prostate cancer. This is shown in a ...

Clinicians report that early AKT inhibition side effects are manageable, allowing four out of five patients to maintain ...

Prostate cancer is one of the most common cancers affecting men worldwide. However, planning personalized radiotherapy in the ...

First patients dosed in OPTIMAL-e1 Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent’s Hospital ...

Men diagnosed with metastatic hormone-sensitive prostate cancer who carry a specific tumor deficiency now have a targeted ...

A noninvasive DNA blood test can identify metastatic castration-resistant prostate cancer (mCRPC) patients who are most ...

PROSTATE CANCER SCREENING initiated before 50 and with lower baseline prostate specific antigen (PSA) levels was associated ...

In this long-term follow-up to the phase 2 ARTO trial, researchers analyzed survival outcomes in patients with CRPC treated with metastasis-directed therapy.

Researchers have uncovered a rare inherited mutation linked to prostate cancer—and it could help identify at-risk families ...

Sept. 18, 2025 -- About 1 in 8 men will face a prostate cancer diagnosis. Early-stage prostate cancer often has no symptoms—so how should men approach screening and advocacy? What disparities do Black ...

Recently published Metastatic Castration-resistant Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, metastatic castration-resistant ...

Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine ...